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INTRODUCTION
Hyperglycemia occurs in 40-80% of very premature, low birthweight 
infants. The pathogenesis of hyperglycemia in critically ill adults and 
preterm infants may differ. The mechanisms responsible for 
hyperglycemia in preterm infants are related to immaturity of the 
glucose regulatory system, in addition to clinical stress.
This condition has been linked to worsened outcomes, including 
increased incidence of sepsis, increased ventilator dependence, 
retinopathy of prematurity, hospital length of stay and mortality
Often, glucose restriction is used to control high blood glucose levels, 
but this can deprive the neonate of crucial energy required to promote 
growth. Continuous insulin infusion has thus been proposed as a 
solution to reduce plasma glucose concentrations and optimize 
nutrition in these small infants. 
However, great heterogeneity is the hallmark of neonatal glucose
metabolism. Thus, the emerging use of insulin carries a significant risk 
of hypoglycemia due to patient response variations to insulin over time.
An adaptive model of the fundamental glucose regulatory dynamics in 
neonates can track an infant’s sensitivity to exogenous insulin in real-
time. Targeted control forecasts the range of likely future glucose 
levels to select the optimal insulin rate, adapting control to the infant’s 
current metabolic state.
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MODELS AND METHODS
A metabolic computer system model, clinically validated in adult intensive 
care patients and virtual trials using neonatal data, is used to provide tight 
control in very low birth weights infants. Median model BG fit error is 2.4% on 
retrospective data and forecast errors are 5.2% to 13.6% for 1 to 4 hour BG 
predictions.
CLINICAL TRIALS
Model-fitted insulin sensitivity during trials. Each line represents 
the hourly evolution of patient sensitivity to exogenous insulin.
Within the relatively small study 
population, a 2.3x spread of dextrose 
infusion rates were used, and an 8.9x 
spread of insulin sensitivity was 
computed. In response, the controller 
used a 7.6x spread of median insulin 
infusion rates.
Seven clinical trials up to 24 hours each were performed based on initial 
blood glucose over 10 mmol/L to initiate insulin. Over all trials median 
BG was 6.9 (IQR: 5.6 – 7.9, 90%CI: 4.6 – 11.2) mmol/L over 74 
measurements. Minimum BG was 3.8 mmol/L.
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A 7.1 40.6 0.0 0.025 7.7 1.04 8.7 6.9 2.1 0.45
B 9.4 54.4 5.0 0.040 6.7 1.16 12.3 4.1 1.7 1.25
C 4.1 23.3 0.0 0.068 8.7 1.19 14.4 5.2 1.7 0.14
D 9.6 55.0 3.0 0.052 6.5 1.08 8.0 5.0 2.5 0.7
E 6.8 39.1 11.0 0.116 9.0 1.12 12.6 6.5 2.1 0.2
F 8.2 47.5 4.5 0.069 7.0 1.23 14.5 3.8 1.7 0.5
G 9.4 54.3 2.0 0.191 8.7 1.17 14.7 5.3 1.9 0.14
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Clinical glycemic variables during trials. Infusion rates are computed as hourly averages. 
BG mean and standard deviation are computed using lognormal statistics. EBM = Expressed Breast Milk.
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Per-patient BG concentration during computerised insulin dosing. 
The shaded region represents the 4-7 mmol/L target band.
Stochastic model forecasts 
drove controller decisions for 
more insulin resistant and/or 
dynamic patients, preventing 
episodes of hypoglycaemia.
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•Change in insulin 
sensitivity contained
•Insulin infusion rate 
adjusted
•More aggressive control 
may have created hypo 
event for this patient
•Controller tolerated 
period of higher BG to 
balance risk of changes 
in patient condition.
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[%]  [mmol/L]
A 19.20% 1.47 33% 83%
B 8.60% 0.52 31% 85%
C 7.60% 0.77 80% 90%
D 8.40% 0.53 33% 100%
E 6.40% 0.48 100% 100%
F 8.50% 0.72 50% 83%
G 5.90% 0.44 92% 100%
Whole cohort 7.60% 0.54 62% 92%
Patient
Median BG prediction 
error (absolute) BG within IQR forecast range
BG within 5%-95% 
forecast range
BG prediction accuracy and stochastic model prediction coverage.Overall cohort BG target error 
was 7.6% (0.54 mmol/L) during 
clinical trials. Distribution of BG 
prediction errors revealed 69% 
and 84% of BG measurements 
within ±10% and ±20% of 
forecasted value.
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SIMULATION STUDIES
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Stochastic forecasting models quantify 
the expected variation of insulin 
sensitivity based on retrospective 
patient data. BG system equations are 
solved using successive values of 
forecasted insulin sensitivity using to 
yield forecast BG range.
Insulin infusions were modulated 
using an iterative bisection 
algorithm to match forecasted BG 
to a pre-determined target based 
on measurements every 2-3 hours 
(max 12 measurements/day). 
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Real-time control trial. Top panel presents measured BG 
concentration (red), model BG target forecasts (blue) and stochastic 
forecast bounds (green). Bottom panel presents insulin infusion rate.
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Simulation studies performed using insulin sensitivity profiles generated 
from 25 retrospective episodes of insulin. Controller refined in-silico
before clinical implementation.
Comparison of percentage of BG measurements within the 4 –
7 mmol/L BG range for retrospective and 2-hour simulated 
control. Each circle represents one of 25 patient profiles.
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Improved control in simulation with up 
to 65% - 82% more measurements 
inside target 4 – 7 mmol/L BG range 
indicated on both per-patient (left) and 
whole-cohort (below) scales. 
(Above) Empirical cumulative distribution functions of 
BG measurements for retrospective hospital control 
versus simulated model-based control trials of 1, 2, 3 
and 4-hour measurement and intervention frequency.
Insulin sensitivity exhibits greater 
inter-patient variance in neonates 
versus adults. Therefore, optimal 
control requires adaptive methods 
in this population.
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(Left) Example of model generated BG response 
(blue) over 1-4 hour prediction interval. Predictions are 
generated assuming a constant insulin sensitivity over 
prediction interval.
